A Billion-Dollar Market to Open "Very Soon"

Generic-drug makers' long wait may finally be over. Bloomberg quoted FDA Commissioner Margaret Hamburg as saying that the agency will have guidance for how to get biosimilars approved "very soon."

That's an untapped multibillion-dollar market, Fools.

Currently, generic-drug makers can get copycat versions of small-molecule drugs approved, but there's isn't a corresponding pathway to get biologics approved. Last year's health-care reform law provided a framework for the FDA to establish one, but the agency hasn't determined the rules yet.

I don't think the agency is dragging its feet; it's just a very complicated issue. Because they're produced in living cells, there are a lot more variables in manufacturing biologics compared to small-molecule drugs that are produced through chemical synthesis. There's a reason they call them biosimilars.

Teva Pharmaceutical (Nasdaq: TEVA  ) hasn't been willing to wait. The drugmaker filed for FDA approval of its biosimilar version of Amgen's (Nasdaq: AMGN  ) Neupogen under the standard FDA approval process for biologic drugs. If it's approved, the drug would technically be a branded drug with all the rights and privileges that go along with that, but it also means it'll have to meet the higher standard.

When the agency finally releases its guidance, the thing investors should look for is whether clinical trials will be required to prove that the biosimilars work the same as their branded counterparts. In addition to delaying biosimilars' entry into the market, clinical trials could be prohibitively expensive, making them not worth developing. Merck (NYSE: MRK  ) was working on an improved version of Amgen's Aranesp, but ditched the idea when the FDA requested a cardiovascular study.

My guess is that the agency will tailor the rules to the individual drugs. Well-characterized drugs will have more lenient rules than those where the variables are less-known. The FDA actually approved one generic biologic years ago, Novartis' (NYSE: NVS  ) Omnitrope, because the company argued that human growth factor was well characterized enough.

I guess we'll know "very soon."

Novartis is a Motley Fool Global Gains choice. The Fool owns shares of Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1445799, ~/Articles/ArticleHandler.aspx, 9/17/2014 3:58:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement